| 3.85 0.17 (4.62%) | 12-03 09:30 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 6.61 | 1-year : | 7.93 |
| Resists | First : | 5.65 | Second : | 6.78 |
| Pivot price | 4.29 |
|||
| Supports | First : | 3.82 | Second : | 3.18 |
| MAs | MA(5) : | 4.13 |
MA(20) : | 4.34 |
| MA(100) : | 3.85  |
MA(250) : | 2.21 |
|
| MACD | MACD : | -0.2 |
Signal : | -0.2 |
| %K %D | K(14,3) : | 23.1 |
D(3) : | 24.6 |
| RSI | RSI(14): 41.6 |
|||
| 52-week | High : | 6.78 | Low : | 0.59 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ IMAB ] has closed above bottom band by 21.6%. Bollinger Bands are 42.8% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 2 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 4.26 - 4.28 | 4.28 - 4.3 |
| Low: | 4.04 - 4.06 | 4.06 - 4.09 |
| Close: | 4.19 - 4.23 | 4.23 - 4.27 |
I-Mab, a clinical stage biopharmaceutical company, discovers, develops, and commercializes biologics to treat cancer and autoimmune disorders. It is developing Felzartamab, a CD38 antibody that is in Phase 1b/2a for patients with membranous nephropathy; Eftansomatropin alfa, a long-acting human growth hormone, which has completed Phase 3 clinical trials to treat pediatric growth hormone deficiency; TJ107, a recombinant human IL-7, which is in Phase 2 for cancer treatment-related lymphopenia and cancer immunotherapy; and Lemzoparlimab, a CD47 monoclonal antibody that has completed Phase 2 clinical trial. Its product candidates also includes Enoblituzumab, a humanized B7-H3 antibody that is in Phase 2 to treat head and neck cancer, and other oncology diseases; Efineptakin, a long-acting recombinant human IL-7, which is in Phase 2 clinical trials to treat lymphopenia and cancer immunotherapy; TJ210, a monoclonal antibody against human C5aR1 that is in Phase 1 for the treatment of cancers and autoimmune; Plonmarlimab, a GM-CSF monoclonal antibody for inflammation and CRS-related therapies; Uliledlimab, a CD73 antibody, which is in Phase 2 clinical trials for treating solid tumors and oncology; TJ-L14B, a PD-L1-based tumor-dependent T-cell engager for solid cancers; and TJ-CD4B, a tumor-dependent T cell engager for gastric and other cancers, as well as TJ-L1IF, a PD-L1/IFN-a antibody-cytokine fusion protein for solid tumors and TJ-C64B, a tumor-dependent T-cell engager for ovarian and other cancers. I-Mab has strategic collaboration agreement with AbbVie Ireland Unlimited Company; Sinopharm Group Co. Ltd.; PT Kalbe Genexine Biologics; and Roche Diagnostics. The company was founded in 2014 and is headquartered in Shanghai, the People's Republic of China.
Wed, 29 Oct 2025
I-MAB (Nasdaq: IMAB) Transitions to NovaBridge Biosciences - GlobeNewswire
Fri, 17 Oct 2025
I-Mab to rebrand as NovaBridge and target Hong Kong dual listing - The Pharma Letter
Thu, 16 Oct 2025
$37M Visara Launch: I-Mab Rebrands as NovaBridge, Pursues Hong Kong IPO and Acquires VIS-101 - Stock Titan
Tue, 14 Oct 2025
I-Mab Biopharma Stock: Caution Warranted After Huge Surge (NASDAQ:IMAB) - Seeking Alpha
Fri, 10 Oct 2025
I-Mab Sponsored ADR (IMAB) Is Up 24.14% in One Week: What You Should Know - Nasdaq
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 115 (M) |
| Shares Float | 98 (M) |
| Held by Insiders | 21.3 (%) |
| Held by Institutions | 21.1 (%) |
| Shares Short | 3,650 (K) |
| Shares Short P.Month | 2,180 (K) |
| EPS | -0.51 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 2.4 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -10.4 % |
| Return on Equity (ttm) | -18.5 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -0.34 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 44 (M) |
| Levered Free Cash Flow | -7 (M) |
| PE Ratio | -7.87 |
| PEG Ratio | 0 |
| Price to Book value | 1.67 |
| Price to Sales | 0 |
| Price to Cash Flow | 10.6 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|